Seasonal Influenza Vaccines: Epidemiology Forecast in Asia-Pacific Markets to 2028
- Pages: 30
- Published: December 2019
- Report Code: GDHCER227-19
Seasonal influenza is a contagious respiratory viral illness. There are four types of seasonal influenza viruses (A, B, C, and D); however, only types A and B cause human disease of public health concern. Influenza transmission occurs when people with flu cough, sneeze, or talk and disseminate droplets. These droplets can land in the mouths or noses of people who then inhale them into the lungs. GlobalData epidemiologists identified country-specific population-based studies published in peer-reviewed journal articles and government-collated surveillance data to build the influenza forecast, and utilized appropriate proxy data where applicable.
In 2018, there were 18,518,017 cases of lab-confirmed seasonal influenza in the 3GM combined. India had the most cases among the 3GM with 9,561,398 cases, followed by China with 7,611,389 cases. By 2028, the 3GM will have very little change in incident cases of lab-confirmed seasonal influenza, with 18,578,681 cases, at an Annual Growth Rate (AGR) of 0.03%.
Vaccination is an effective way to prevent influenza in the youngest population, as vaccine effectiveness is the strongest in younger populations. However, vaccination rates in China and India remain extremely low, at around 1–2% in the general population. In Japan, vaccination is better, at 29% in 2018 for the general population and 40% for ages 0–4 years. However, vaccination rates in Japan are low compared with Western markets, such as the US, where up to 70% of children ages 0–4 years are vaccinated.
The Seasonal Influenza in Asia-Pacific Markets Epidemiology Report and Model provide an overview of the risk factors and global trends of seasonal influenza in the three Asia-Pacific growth markets (3GM: China, India, and Japan).
This report also includes a 10-year epidemiological forecast for the following segmentations in all ages across the 3GM: the diagnosed incident cases of lab-confirmed seasonal influenza, lab-confirmed seasonal influenza mortality, and vaccination rates for seasonal influenza.
The seasonal influenza epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 3GM.
• The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Reasons to buy
The Seasonal Influenza Epidemiology series will allow you to:
Develop business strategies by understanding the trends shaping and driving the Asia-Pacific seasonal influenza market.
Quantify patient populations in the global seasonal influenza market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for seasonal influenza vaccines in each of the markets covered.
Understand magnitude of lab-confirmed seasonal influenza mortality and the population receiving seasonal influenza vaccination.
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Seasonal Influenza: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for Seasonal Influenza (2018–2028)
3.5.1 Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza
3.5.2 Age-Specific Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza
3.5.3 Sex-Specific Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza
3.5.4 Lab-Confirmed Seasonal Influenza Mortality
3.5.5 Age-Specific Vaccination of Seasonal Influenza
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis
4.2 About the Authors
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
List of Tables
Table 1: Risk Factors and Comorbidities for Seasonal Influenza
List of Figures
Figure 1: 3GM, Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza, Both Sexes, All Ages, 2018 and 2028, N
Figure 2: Diagnosed Incidence of Lab-Confirmed Seasonal Influenza, Men and Women, All Ages, Cases per 100,000 Population, 2018
Figure 3: 3GM, Sources Used and Not Used for Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza
Figure 4: 3GM, Sources Used for Lab-Confirmed Seasonal Influenza Mortality
Figure 5: 3GM, Sources Used for Proportion of People Receiving Seasonal Influenza Vaccination
Figure 6: 3GM, Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza, Both Sexes, All Ages, 2018
Figure 7: 3GM, Age-Specific Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza, Both Sexes, All Ages, 2018, N
Figure 8: 3GM, Sex-Specific Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza, All Ages, 2018, N
Figure 9: 3GM, Lab-Confirmed Seasonal Influenza Mortality, Both Sexes, All Ages, 2018, N
Figure 10: 3GM, Age-Specific Cases of People Receiving Seasonal Influenza Vaccination, Both Sexes, All Ages, 2018, N